Halozyme Therapeutics: Peers

The FY2025 (Dec) proxy of Halozyme Therapeutics names 18 peer companies for pay. Among Halozyme Therapeutics and these peers, CEO pay was 3rd highest of 9 and total shareholder return was 4th highest of 9.

3rd highest of 9in Halozyme Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:

$6.9M$33.2M

4th highest of 9in Halozyme Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:

$68$523

Pay peer group, FY2025 (Dec) proxy

Exelixis
PTC Therapeutics
Biomarin Pharmaceutical
United Therapeutics
INSMED
Ionis Pharmaceuticals
Alkermes plc.
Neurocrine Biosciences
Acadia PharmaceuticalsNot disclosedNot disclosed
Amicus TherapeuticsNot disclosedNot disclosed
Apellis PharmaceuticalsNot disclosedNot disclosed
BeiGeneNot disclosedNot disclosed
Blueprint MedicinesNot disclosedNot disclosed
Denali TherapeuticsNot disclosedNot disclosed
Intra-Cellular TherapeuticsNot disclosedNot disclosed
Ironwood PharmaceuticalsNot disclosedNot disclosed
Sarepta TherapeuticsNot disclosedNot disclosed
Ultragenyx PharmaceuticalsNot disclosedNot disclosed
18 companies

PSU comparator group

The companies that relative total shareholder return is measured against for performance stock units.

NASDAQ Biotechnology Index (index)Not disclosedNot disclosed
1 company

Changes by year

FY2025 (Dec) proxy

  • AddedApellis Pharmaceuticalspay peer group•Apellis Pharmaceuticals, Denali Therapeutics, and Intra-Cellular Therapeutics were added to the group based on the Compensation Committee’s assessment of the criteria noted above
  • AddedDenali Therapeuticspay peer group•Apellis Pharmaceuticals, Denali Therapeutics, and Intra-Cellular Therapeutics were added to the group based on the Compensation Committee’s assessment of the criteria noted above
  • AddedIntra-Cellular Therapeuticspay peer group•Apellis Pharmaceuticals, Denali Therapeutics, and Intra-Cellular Therapeutics were added to the group based on the Compensation Committee’s assessment of the criteria noted above
  • RemovedAlnylam Pharmaceuticalspay peer group•Alnylam Pharmaceuticals and Ligand Pharmaceuticals were removed from the group based on the Compensation Committee’s assessment that it no longer met the defined size
  • RemovedLigand Pharmaceuticalspay peer group•Alnylam Pharmaceuticals and Ligand Pharmaceuticals were removed from the group based on the Compensation Committee’s assessment that it no longer met the defined size

FY2024 (Dec) proxy

  • AddedBeiGenepay peer group•BeiGene, Insmed, and PTC Therapeutics were added to the group based on the Compensation Committee’s assessment of the criteria noted above
  • AddedInsmedpay peer group•BeiGene, Insmed, and PTC Therapeutics were added to the group based on the Compensation Committee’s assessment of the criteria noted above
  • AddedPTC Therapeuticspay peer group•BeiGene, Insmed, and PTC Therapeutics were added to the group based on the Compensation Committee’s assessment of the criteria noted above
  • RemovedAgios Pharmaceuticalspay peer group•Agios Pharmaceuticals was removed from the group based on the Compensation Committee’s assessment that it no longer met the revenue and market capitalization criteria

FY2023 (Dec) proxy

  • AddedAlkermes plc.pay peer group•Alkermes, BioMarin Pharmaceutical and United Therapeutics were added to the group based on the Compensation Committee’s assessment of the criteria noted above
  • AddedBiomarin Pharmaceuticalpay peer group•Alkermes, BioMarin Pharmaceutical and United Therapeutics were added to the group based on the Compensation Committee’s assessment of the criteria noted above
  • AddedUnited Therapeuticspay peer group•Alkermes, BioMarin Pharmaceutical and United Therapeutics were added to the group based on the Compensation Committee’s assessment of the criteria noted above
  • RemovedAcceleron Pharmaceuticalspay peer groupbecause it was no longer publicly-traded
  • RemovedFibroGenpay peer groupbecause it was no longer publicly-traded
  • RemovedHeron Therapeuticspay peer groupbecause it was no longer publicly-traded
  • RemovedNektar Therapeuticspay peer groupbecause it was no longer publicly-traded

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.